Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes

Preethi Mani; Kiyoko Uno; Julie St. John; Stuart Kupfer; Alfonso Perez; E. Murat Tuzcu; Stanley L. Hazen; Steven E. Nissen; Stephen J. Nicholls

doi:10.1016/j.jacc.2015.05.023

Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes

Preethi Mani, Kiyoko Uno, Julie St. John, Stuart Kupfer, Alfonso Perez, E. Murat Tuzcu, Stanley L. Hazen, Steven E. Nissen, Stephen J. Nicholls

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	328-329
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	66
Issue number	3
DOIs	https://doi.org/10.1016/j.jacc.2015.05.023
State	Published - Jul 21 2015
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2015.05.023

Cite this

Mani, P., Uno, K., St. John, J., Kupfer, S., Perez, A., Tuzcu, E. M., Hazen, S. L., Nissen, S. E., & Nicholls, S. J. (2015). Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes. Journal of the American College of Cardiology, 66(3), 328-329. https://doi.org/10.1016/j.jacc.2015.05.023

Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes. / Mani, Preethi; Uno, Kiyoko; St. John, Julie et al.
In: Journal of the American College of Cardiology, Vol. 66, No. 3, 21.07.2015, p. 328-329.

Research output: Contribution to journal › Letter › peer-review

Mani, P, Uno, K, St. John, J, Kupfer, S, Perez, A, Tuzcu, EM, Hazen, SL, Nissen, SE & Nicholls, SJ 2015, 'Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes', Journal of the American College of Cardiology, vol. 66, no. 3, pp. 328-329. https://doi.org/10.1016/j.jacc.2015.05.023

@article{961b72ed428a4294a6399fc1fb1c088f,

title = "Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes",

author = "Preethi Mani and Kiyoko Uno and {St. John}, Julie and Stuart Kupfer and Alfonso Perez and Tuzcu, {E. Murat} and Hazen, {Stanley L.} and Nissen, {Steven E.} and Nicholls, {Stephen J.}",

note = "Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi, Resverlogix, and Eli Lilly; and is a consultant/advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, CSL Behring, Boehringer Ingelheim, Takeda, Roche, NovoNordisk, LipoScience, Amgen, Omthera, Reseverlogix, and Anthera; and has received research support from AstraZeneca, Eli Lilly, Amgen, Takeda, Roche, Novartis, Anthera, Resverlogix, and Lipid Sciences. Drs. Perez and Kupfer are employees of Takeda Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2015",

month = jul,

day = "21",

doi = "10.1016/j.jacc.2015.05.023",

language = "English (US)",

volume = "66",

pages = "328--329",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "3",

}

TY - JOUR

T1 - Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes

AU - Mani, Preethi

AU - Uno, Kiyoko

AU - St. John, Julie

AU - Kupfer, Stuart

AU - Perez, Alfonso

AU - Tuzcu, E. Murat

AU - Hazen, Stanley L.

AU - Nissen, Steven E.

AU - Nicholls, Stephen J.

N1 - Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi, Resverlogix, and Eli Lilly; and is a consultant/advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, CSL Behring, Boehringer Ingelheim, Takeda, Roche, NovoNordisk, LipoScience, Amgen, Omthera, Reseverlogix, and Anthera; and has received research support from AstraZeneca, Eli Lilly, Amgen, Takeda, Roche, Novartis, Anthera, Resverlogix, and Lipid Sciences. Drs. Perez and Kupfer are employees of Takeda Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2015/7/21

Y1 - 2015/7/21

UR - http://www.scopus.com/inward/record.url?scp=84937426645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937426645&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2015.05.023

DO - 10.1016/j.jacc.2015.05.023

M3 - Letter

C2 - 26184626

AN - SCOPUS:84937426645

SN - 0735-1097

VL - 66

SP - 328

EP - 329

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 3

ER -

Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this